Detect Serum Circulating EGFR Mutation With Amplification Refractory Mutation System Method From Patients With Non-small-celi Lung Cancer

Objective:To explore the feasibility of the application of peripheral blood alternatives oftumor tissue to detect EGFR(epidermal growth factor receptor)mutation inNSCLC(non small cell lung cancer)by ARMS(amplification refractory mutationsystem)．Methods:I collect tumor tissues and paired peripheral venous blood of68patients fromthoracic surgery of the first affiliated hospital of nanchang university,all patientsaccepted surgical treatment,these samples were extracted the DNA by QIAGENDNA extraction kit, and then detected EGFR gene mutation by the AmoyDx human21EGFR gene mutation detection kits,we analyzed the relationship between EGFRgene mutation and clinical feature in peripheral blood and tumor tissue of NSCLCpatients, furthermore to compare the consistency of EGFR gene mutations inperipheral blood and tumor tissue.by using chi-square test.and analyzed therelationship between different mutation type and clinical feature.results:1、 EGFR mutations of tumor tissue and peripheral blood was higher inadenocarcinoma than Squamous cell carcinoma (52.9%vs20.6%, P=0.006,52.9%vs5.9%P <0.05), In age, gender, smoking status.,EGFR mutations had no significantdifference (P>0.05)2、68cases of paired samples,EGFR mutation rate of peripheral blood was29.4％(20／68), EGFR mutation rate of tumor tissue was36.8%(25/68), Theconsistency of EGFR mutations with tumor tissue and peripheal blood reached80%，EGFR mutation rate of them had no significant difference (p>0.05).3、EGFR mutation of exon19and exon21is in the highest flight,Two types ofmutation had no significant difference in sex, age, smoking status,pathological stageand pathological type.(p>0.05)conclusions: We can verified which tissue samples is still the gold standard, for the EGFRmutation testing in NSCLC patients. patients with advanced lung cancer can useperipheral blood for testing EGFR mutation, so screening patients of TKIs targetedtherapy.EGFR gene mutation detection is feasible by using Free DNA in plasma.